Paula Klein

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 854 citations

End-of-study Results, Breast Oncology, Medicine +8

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102

Noah Kornblum, Fengmin Zhao, Judith Manola et al. · Journal of Clinical Oncology · 2018 · 184 citations · Full text

Breast Oncology, Estrogen Receptor, Gynecology +19

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Hope S. Rugo, Paula Klein, Susan A. Melin et al. · JAMA · 2017 · 174 citations · Full text

Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine-needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment.

W. Fraser Symmans, Matthew Volm, Richard L. Shapiro et al. · PubMed · 2000 · 152 citations

Breast Oncology, Cancer Management, Pathology +16

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer

Mohammad Jahanzeb, Joanne Mortimer, Furhan Yunus et al. · The Oncologist · 2002 · 144 citations · Full text